Clinical trials: Untreated
Hyperlipoproteinemia Type I
Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
LPL (Lipoprotein Lipase) is an enzyme which plays an important role in the elimination of triglycerides (fat) and the clearance of dietary fat particles known as chylomicrons (CM) in the blood.
- Trial name
- NCT01447901
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Amsterdam Molecular Therapeutics
Leukemia, Myeloid, Acute
BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients
- Trial name
- NCT00632749
- Testing
- BI 811283 (d 1 and 15), Cytarabine, BI 811283 (d1)
- Where
- 7 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01835158
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
- Where
- 488 sites in United States
- Volunteers
- 157 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs.
- Trial name
- NCT00004217
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 90 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- SWOG Cancer Research Network
Melanoma Metastatic
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
The association between microbiota and response to ICI-based therapy reflects the ability of bacterial metabolites to upregulate MHC class I APM component expression and/or function in cancer cells, leading to their elimination…
- Trial name
- NCT07050940
- Testing
- Postbiotic, AntiPD1
- Where
- 5 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Ospedaliera di Perugia
Gingival Recession, Orthodontic Treatment
Gingival Recessions in Orthodontically Treated and Untreated Adult Patients
To identify the predisposing parameters for gingival recessions in adult patients seeking orthodontic treatment. The ultimate aim is to provide a clinical guideline to estimate the risk of developing post-orthodontic gingival…
- Trial name
- NCT07445555
- Testing
- Registration of parameters
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-Hodgkin Lymphoma
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Although the cause(s) of clinical drug resistance in non-Hodgkin's lymphomas (NHL) are unknown, in vitro studies suggest that abnormalities of the cell cycle and mechanisms of apoptosis may play an important role.
- Trial name
- NCT00026910
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients (PUPs) with haemophilia A.
- Trial name
- pathfinder™6 (NCT02137850)
- Testing
- turoctocog alfa pegol
- Where
- 96 sites in United States, Algeria and 21 more
- Volunteers
- 124 people
- Sponsor
- Novo Nordisk A/S
Acute Myelogenous Leukemia, AML
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and…
- Trial name
- NCT02287233
- Testing
- Venetoclax, Cytarabine
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 94 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
This is a prospective, open, non-randomized, non-controlled, phase II, clinical trial for treatment of newly diagnosed AML patients, younger than 66 years. Trial is based on: INDUCTION: FLAI + Gemtuzumab-Ozogamicin (FLAI-GO).
- Trial name
- MYFLAI07 (NCT00909168)
- Testing
- FLAIMy - Fluda, Ida, Ara-C, Mylotarg
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- University Hospital, Udine, Italy
Pancreatic Cancer
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00126633
- Testing
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Francisco
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Chronic Myeloid Leukemia in Myeloid Blast Crisis, Untreated Adult Acute Myeloid Leukemia
Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
The current standard therapy in previously untreated adults with chronic phase (CP) of CML is imatinib and the result of long-term follow-up of IRIS study proves that imatinib for CML CP is reasonable therapy.(1, 2) However, some…
- Trial name
- NICE-BORA (NCT01690065)
- Testing
- Nilotinib+AD induction
- Where
- 2 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Ulsan University Hospital
Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic…
- Trial name
- HARMONi-GU1 (NCT07815665)
- Testing
- Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Summit Therapeutics
Melanoma
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people…
- Trial name
- NCT05912244
- Testing
- IO102/IO103, Nivolumab-Relatlimab
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Small Cell
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.
- Trial name
- COMBAT (NCT00826644)
- Testing
- Belotecan, Etoposide, Cisplatin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Chonnam National University Hospital
Waldenström Macroglobulinemia (WM)
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
This study is a prospective phase II clinical trial designed to evaluate the deep response rate of the ZBR regimen (zanubrutinib combined with reduced-dose bendamustine and CD20 Monoclonal Antibody ) in treatment-naïve…
- Trial name
- ZBR in WM (NCT07259122)
- Testing
- Zaunbrutinib, Bendamustine and Rituximab for induction therapy, Zanubrutinib mono therapy for maintenance treatment
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Sarcoma
Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, methotrexate, cisplatin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00645632
- Testing
- cisplatin, doxorubicin hydrochloride, ifosfamide
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Uveal Melanoma
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
- Trial name
- NCT03070392
- Testing
- IMCgp100, Dacarbazine, Ipilimumab
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 378 people
- Sponsor
- Immunocore Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.